Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) – the leading organization and collective voice of medical imaging and radiopharmaceutical manufacturers, innovators, and product developers – has recently held a Positron Emission Tomography Drugs: Product Quality Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations event co-hosted with the U.S. Food and Drug Administration’s (FDA) Office of New Drugs (OND), Office of Regulatory Operations (ORO), and Division of Regulatory Operations for Specialty Medicine (DRO-SM), as well as the Society of Nuclear Medicine...